Company intelligence / Profile preview
Intellipharmaceutics
Toronto, Ontario, Canadaintellipharmaceutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Intellipharmaceutics has developed a pipeline of both novel and generic extended-release oral drugs using its proprietary Hypermatrix™ technology. The company’s lead programs include an abuse-deterrent oxycodone ER formulation and Regabatin XR for neuropathic pain. Several ANDA generics are at various stages from clinical studies to FDA review or approval, with some commercialized through partners[10][6][8].
- Therapeutic areas
- PsychiatryGastroenterologyNeurologyEndocrinology
- Modalities
- Small moleculeDrug delivery technology (Hypermatrix platform)Extended-release oral solid dosage
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Par Pharmaceutical Inc. – commercialization partner for Focalin XR generic and others[2][8]Taro Pharmaceuticals – exclusive licensee for desvenlafaxine ER tablets in Canada[6]
Beyond the preview
Go deeper on Intellipharmaceutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intellipharmaceutics.